Accepted Articles
Back to the articles list |
Back to browse issues page
1- Dental Sciences Research Center, Department of Periodontology, School of Dentistry, Guilan University of Medical Sciences, Rasht, Iran
2- Dental Sciences Research Center, Department of Periodontology, School of Dentistry, Guilan University of Medical Sciences, Rasht, Iran ,dr.bardia_vad@yahoo.ccom
2- Dental Sciences Research Center, Department of Periodontology, School of Dentistry, Guilan University of Medical Sciences, Rasht, Iran ,
Abstract: (94 Views)
Introduction: This systematic review evaluates the role of bone morphogenetic proteins (BMPs) in enhancing osseointegration in dental implant therapy. Despite generally high implant success rates, early failures still occur, primarily due to insufficient initial osseointegration and limited bone regeneration capacity.
Materials and Methods: This systematic review was conducted using PubMed, Scopus, and Web of Science databases. Studies published between January 2010 and September 2025 were evaluated (final search: September 30, 2025). Twelve studies were included, comprising both clinical and preclinical investigations. Extracted data included study characteristics, BMP type and dosage, delivery method, and outcome measures.
Results: Among the included studies, four were clinical and eight were preclinical. The lowest tested dose in animal models was 0.2 µg using a calcium phosphate carrier. In clinical studies, BMPs were delivered using xenografts, collagen, or HA/TCP carriers at concentrations ranging from 0.25 mg/mL to 1.5 mg/mL Across studies, BMP application demonstrated early improvements in bone formation, implant stability, and bone-to-implant contact (BIC), particularly during short-term follow-up periods. However, these early benefits did not consistently translate into sustained long-term advantages, with group differences often diminishing at later follow-up.
Conclusions: Although BMPs enhance early osseointegration and initial peri-implant bone formation, their long-term clinical benefits remain inconsistent across available studies.
Materials and Methods: This systematic review was conducted using PubMed, Scopus, and Web of Science databases. Studies published between January 2010 and September 2025 were evaluated (final search: September 30, 2025). Twelve studies were included, comprising both clinical and preclinical investigations. Extracted data included study characteristics, BMP type and dosage, delivery method, and outcome measures.
Results: Among the included studies, four were clinical and eight were preclinical. The lowest tested dose in animal models was 0.2 µg using a calcium phosphate carrier. In clinical studies, BMPs were delivered using xenografts, collagen, or HA/TCP carriers at concentrations ranging from 0.25 mg/mL to 1.5 mg/mL Across studies, BMP application demonstrated early improvements in bone formation, implant stability, and bone-to-implant contact (BIC), particularly during short-term follow-up periods. However, these early benefits did not consistently translate into sustained long-term advantages, with group differences often diminishing at later follow-up.
Conclusions: Although BMPs enhance early osseointegration and initial peri-implant bone formation, their long-term clinical benefits remain inconsistent across available studies.
Send email to the article author
| Rights and permissions | |
 | This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |